Takeda Pharmaceutical Company Limited (TAK) Stock Analysis
Takeda is a leveraged but cash-generative pharma turnaround, priced for patent-cliff distress while its next wave of blockbuster launches could unlock meaningful upside.
Overview
Takeda is a global, R&D-driven biopharma company focused on gastroenterology, neuroscience, rare diseases, plasma-derived therapies, oncology, and vaccines. FY2025 core revenue was JPY 4,505.7 billion, or about $28.3 billion, with the U.S. representing 48% of sales. Vyvanse generic erosion remains the main near-term drag, but Growth and Launch Products now exceed 52% of revenue, supported by Entyvio, Gammagard, Takhzyro, and a late-stage pipeline with multiple blockbuster launch opportunities.